Cipla names Dr Mandar Purushottam Vaidya as Additional, Independent Director
New Delhi: Cipla has announced the appointment of Dr. Mandar Purushottam Vaidya as an additional and independent director of the Company for period of 5 years with effect from 29th July 2022 to 28th July 2027 (both days inclusive).
"The Board of the Directors at its meeting held today i.e., on 29th July 2022, has appointed Dr. Mandar Purushottam Vaidya as an additional and independent director of the Company for period of 5 years with effect from 29th July 2022 to 28th July 2027 (both days inclusive)," Cipla stated in a BSE filing.
Dr. Mandar Vaidya is a medical doctor and a management graduate from the Jamnalal Bajaj Institute of Management Studies, India.
He spent 15 years at McKinsey (2002-2017), the last seven as a partner where he co-led the healthcare practice in India and established the hospitals practice for Asia. He has served leading pharmaceutical companies in India and globally, across several areas such as core strategy, manufacturing productivity improvement, R&D productivity, portfolio management, M&A and procurement programs.
From 2017 to 2019, he worked part time, advising several healthcare companies, providing leadership coaching and designing and teaching a course on problem solving at Ashoka University.
In August 2019, he joined OYO, a global travel-tech company as CEO - SE Asia & Middle East, driving growth, doubling the number of-hotels and homes, while transforming the regions contribution margin to a net positive territory. He led the business through the COVID crisis, improving EBIDTA loss to a negligible level while managing massive business disruptions.
Since March 2021 he is the CEO - OYO Vacation Homes (OVH), Europe, a strategically important core market for the company. OVH ·is Europe's second largest vacation homes company. He leads three acquired brands, DanCenter, Belvilla and Traum FW, each with a multi decade legacy. He has turbo charged their growth and profitability by migrating them into a tech forward environment while retaining the uniqueness of each business built over the last several decades.
Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. The Company was founded by Khwaja Abdul Hamied in 1935 in Mumbai.
Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control, depression, and other medical conditions.
Read also: Cipla Gets CDSCO Panel Nod To Study Inhaled Itraconazole Dry Powder for inhalation
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.